A Rare Survival, and a Risky Choice

In June 2026, Professor Richard Scolyer, an Australian pathologist and cancer researcher who had just won the country's Australian of the Year award alongside his longtime partner, died from glioblastoma — one of the deadliest forms of brain cancer. He was 59.

What made his final two years significant was not just that he outlived the typical timeline for his disease. It was what he chose to do with that time. Scolyer became the first person in the world to try a new approach: receiving immunotherapy before surgery to remove his brain tumour, applying techniques he had spent his career developing for melanoma. According to ABC News, most glioblastoma patients survive around 12 months after diagnosis. Scolyer's survival of roughly two years already exceeded that benchmark.

Who He Was

Scolyer built his reputation at the Melanoma Institute of Australia in Sydney, where he worked as co-medical director with Professor Georgina Long. Together, they helped transform melanoma from a near-certain death sentence into a treatable disease. When melanoma spreads (becomes metastatic), it was once devastating. By the early 2000s, survival rates for advanced melanoma were grim.

Scolyer and Long's work centred on a type of treatment called immunotherapy — drugs that essentially wake up the body's own immune system to fight cancer cells. Their research helped prove that immunotherapy could be a first-line treatment for advanced melanoma, not a last resort. In January 2024, Prime Minister Anthony Albanese named them joint Australian of the Year for this achievement. Reuters noted that Scolyer had spent his career translating discoveries made in the laboratory into treatments that actually saved lives.

The Diagnosis and the Experiment

Glioblastoma multiforme (GBM) is exceptionally hard to treat. The cancer cells multiply rapidly and spread through the brain tissue. After standard treatment — surgery, chemotherapy, and radiation — the cancer almost always returns. Median survival is around 15 months, and very few patients live five years.

When Scolyer was diagnosed in 2024, the odds were against him. But he and Long devised an experimental plan. Rather than waiting until after surgery to give immunotherapy, they tried giving it before — a reversal of the usual sequence. The thinking was straightforward: an intact tumour sitting in the brain might be a richer source of cancer markers that could prime the immune system to mount a stronger, longer-lasting response than treating what remained after surgery. According to ABC News, this neoadjuvant approach had never been tried for brain cancer before.

This is not an unusual pattern in medical history. Researchers who become patients sometimes use their expertise to try experimental approaches rather than accept standard outcomes. It is ethically complicated, but these kinds of detailed case studies occasionally generate the early signals that reshape entire research programmes.

Why This Matters Beyond One Person

One patient's case — even a meticulously documented one run by world-class clinicians — cannot prove a new treatment works. But it can generate crucial biological data: snapshots of how immune cells infiltrate the tumour, how the tumour's immune environment changes before and after treatment, and how the drug moves through the blood-brain barrier (the tightly controlled boundary that separates blood from brain tissue).

The blood-brain barrier is a major obstacle in brain cancer research. Many cancer drugs that work well against tumours elsewhere in the body cannot cross it effectively, or lose their power when they do. Immunotherapy drugs appear more promising at crossing this barrier than older chemotherapy agents, but this remains an active area of study. Scolyer's case adds a human data point to a field that has very few of them.

The sequencing question — treat before surgery or after — is genuinely important. In breast cancer, giving immunotherapy before surgery has shown strong results that correlate with long-term survival. In lung cancer, a similar pre-surgery approach has moved from experimental trials into standard treatment guidelines. Whether the same strategy makes sense for glioblastoma, a tumour known for suppressing immune responses, is still an open question. The brain has its own immune privilege — it does not invite the same immune scrutiny as other organs — which makes the parallel imperfect.

There is real scientific value in attempting to answer that question, even through a single carefully documented case.

What the Institute Will Carry Forward

Scolyer's death does not erase what he and his colleagues built. The Melanoma Institute of Australia has accumulated decades of research infrastructure, clinical trial networks, and patient data. That institutional knowledge remains. Long continues at the institute, as does the broader research team. Australia holds a distinctive position in global melanoma research, partly because melanoma is so common there — due to sun exposure and population demographics — which means the institute's work carries particular weight.

The 2024 Australian of the Year award itself was notable for recognising not just scientific discovery, but clinical translation: the hard work of moving lab findings through trials and into hospital wards. That shift in recognition matters because translation is often undervalued, even though it is where research meets patients.

For brain cancer researchers, Scolyer's case will likely become part of the published record — a documented attempt to apply melanoma immunotherapy strategies to the brain. Whether it influences how future trials are designed will depend on what his team learns from the biological samples collected before and after his treatment.

The Larger Landscape

Glioblastoma research is at a crossroads. An experimental vaccine called rindopepimut failed its pivotal trial nearly a decade ago. A device called Optune (which uses electrical fields to disrupt cancer cells) has added modest survival benefits. Early CAR-T approaches — where immune cells are engineered to attack cancer — are still in testing. The problem is stark: immunotherapy has revolutionised treatment for melanoma, lung cancer, and kidney cancer, but it has not yet transformed glioblastoma outcomes in the same way.

One meticulously studied case will not solve that puzzle. Oncology is full of compelling single cases that never led anywhere. But Scolyer's case documents something unambiguous: a senior clinician-researcher who understood the data, carried the standing to push through an experimental protocol, and made a calculated bet on his own survival in full public view. He lost that bet, as the disease usually wins. Yet he lived longer than the median, and the data his case generated may seed future trials that others will pursue.

That matters, even if the immediate outcome is not what anyone hoped.